We found that X55 preferentially targeted CDA-deficient tumor cells, although two CDA-expressing tumor cell lines were also sensitive, and that X55 had no effect on the growth of nonmalignant cells, regardless of their CDA expression status, or on CDA-expressing HeLa-Ctrl cells in which CDA activity had been inhibited. This evidence concerns the gene CDA and neoplasm.